BS_1EBQ3T20
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 230.74901445466492
- age_years
- 3.447
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.677
- MYC_TARGETS_V1+0.626
- G2M_CHECKPOINT+0.607
- MYC_TARGETS_V2+0.480
- PANCREAS_BETA_CELLS+0.392
- PROTEIN_SECRETION+0.340
- DNA_REPAIR+0.272
- UNFOLDED_PROTEIN_RESPONSE+0.259
- WNT_BETA_CATENIN_SIGNALING+0.243
- MITOTIC_SPINDLE+0.240
Top 10 suppressed
- MYOGENESIS-0.351
- BILE_ACID_METABOLISM-0.344
- APICAL_SURFACE-0.332
- INTERFERON_ALPHA_RESPONSE-0.294
- KRAS_SIGNALING_DN-0.277
- ADIPOGENESIS-0.272
- P53_PATHWAY-0.245
- ESTROGEN_RESPONSE_EARLY-0.240
- CHOLESTEROL_HOMEOSTASIS-0.221
- INTERFERON_GAMMA_RESPONSE-0.213
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934937 | — | — | 0.877 |
| 2 | SRR934990 | — | — | 0.866 |
| 3 | SRR934893 | — | — | 0.859 |
| 4 | 293E6D35-8392-4C44-BC18-F917989516B0 | — | — | 0.855 |
| 5 | BS_A0DYVX9J | high-grade glioma | — | 0.844 |
| 6 | C635C019-A66D-42B7-911C-4D0742CAF95A | — | — | 0.840 |
| 7 | SRR934900 | — | — | 0.837 |
| 8 | MNG732 | — | — | 0.833 |
| 9 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.831 |
| 10 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.677 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.626 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.607 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.392 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.272 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.259 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.243 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.219 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.173 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.159 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.139 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.138 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.137 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.131 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.071 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.066 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.043 | Idelalisib | — uncovered |